Elsevier

Autoimmunity Reviews

Volume 16, Issue 4, April 2017, Pages 377-384
Autoimmunity Reviews

Review
Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature

https://doi.org/10.1016/j.autrev.2017.02.008Get rights and content

Highlights

  • IVIG therapy is a safe therapeutic option in SSc patients.

  • IVIG may improve muscle, joint and digestive tract involvements in SSc patients.

  • IVIG may facilitate corticosteroid tapering in SSc patients.

Abstract

Background

As intravenous immunoglobulins (IVIG) exhibit immunomodulatory and antifibrotic properties, they may be a relevant treatment for systemic sclerosis (SSc). The objectives of this work were thus to report on the efficacy and safety of IVIG in a population of SSc patients and to review the available literature.

Methods

46 patients from 19 French centers were retrospectively recruited. They were included if they had a diagnosis of SSc and received at least 1 IVIG infusion at a dosage > 1 g/kg/cycle. Relevant data collected at IVIG discontinuation were compared to those collected at IVIG initiation. A comprehensive literature review was performed.

Results

We observed a significant improvement of muscle pain (74% vs. 20%, p < 0.0001), muscle weakness (45% vs. 21%, p = 0.01), joint pain (44% vs. 19%, p = 0.02), CK levels (1069 ± 1552 UI vs. 288 ± 449 UI, p < 0.0001) and CRP levels (13.1 ± 17.6 mg/L vs. 9.2 ± 16.6 mg/L, p = 0.001). We also noted a trend for an improvement of gastro-esophageal reflux disease (68% vs. 53%, p = 0.06) and bowel symptoms (42% vs. 27%, p = 0.06). Skin and cardiorespiratory involvements remained stable. Finally, corticosteroid daily dose was significantly lower by the end of treatment (13.0 ± 11.6 mg/day vs. 8.9 ± 10.4 mg/day, p = 0.01). Only two severe adverse events were reported (one case of deep vein thrombosis and one case of diffuse edematous syndrome).

Conclusion

Our work suggests that IVIG are a safe therapeutic option that may be effective in improving musculoskeletal involvement, systemic inflammation, digestive tract symptoms and could be corticosteroid sparing.

Introduction

Systemic sclerosis (SSc) is a rare and severe condition classified within the connective tissue diseases [1]. It is associated with several debilitating complications (notably digital ulcers, interstitial lung disease (ILD), pulmonary hypertension and digestive tract fibrosis) [2] that greatly impact health-related quality of life [3]. SSc pathophysiology is complex and combines, to different degrees, a fibrotic (excessive synthesis of collagen fibers by activated fibroblasts), vascular (microangiopathy) and immunological (dysregulation of cellular and humoral immune systems) components on a background of genetic predisposition and environmental exposure [4], [5]. Current standard of care for management of severe organ involvements is based on symptomatic treatments (such as vasodilators in pulmonary arterial hypertension [6]) and immune-targeted therapies [7] (from conventional immunosuppressants and biologics to hematopoietic stem cell transplantation). However, there are currently no therapeutic strategies specifically aimed at preventing or reversing fibrogenesis [8], a major phenomenon in SSc pathogenesis.

Intravenous immunoglobulins (IVIG) have long been used as a therapeutic option in various autoimmune diseases [9], [10], such as immune thrombocytopenia, idiopathic inflammatory myopathies, myasthenia gravis, Guillain-Barré syndrome, Kawasaki disease, ANCA-associated vasculitides and systemic lupus erythematosus. Their foremost advantage is an excellent safety profile [11]: in particular, they are not associated with an increased risk of infection, a very unique feature within the therapeutic armamentarium of these diseases. Although their precise mode of action remains debated, IVIG have been shown to display both immunomodulatory [12] and antifibrotic [13] properties. This gives a pathophysiological relevance to their use as a potential treatment in SSc [14].

Several previous works have suggested the efficacy of IVIG therapy on skin, muscle, joint and digestive tract involvements [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31]. However, most of these studies were case series or open-label single-center trials performed on limited patient samples.

To address these issues, we performed a retrospective multicenter study and assess the efficacy and safety of IVIG on several SSc organ involvements on a large nationwide patient cohort, as well as reviewed the available literature.

Section snippets

Patient selection

Patients were recruited from 19 tertiary care centers across France. They were included in the study if they fulfilled all the following criteria: (1) a definite diagnosis of SSc according to the 2013 American College of Rheumatology (ACR)/European League against Rheumatism (EULAR) classification criteria [32]; (2) administration of at least one IVIG cycle; (3) completion of at least one follow-up visit; (4) an age over 18 years old. They were excluded if IVIG were prescribed exclusively for

Baseline characteristics of the study population

Overall, the study population comprised 46 patients (Table 1). Most of them were middle-aged females (sex ratio m/f: 0.24, mean age 51.3 ± 15.4 years old) recently diagnosed (4.1 ± 5.2 years before) with a diffuse cutaneous form of the disease (59%) associated with anti-topoisomerase I (27%) or anti-centromere antibodies (20%). A vast majority of patients had an overlap syndrome with another connective tissue disease, especially with idiopathic inflammatory myopathies (85%).

Major organ involvements

Discussion and review of the literature

In this study, we tried to report on the efficacy and safety of IVIG treatment in a large multi-center cohort of SSc patients. Our results can be summarized as follows: (1) IVIG therapy may improve musculoskeletal involvement, systemic inflammation, corticosteroid tapering, and possibly digestive tract symptoms, in SSc patients; (2) IVIG are a globally well-tolerated treatment in these patients.

Our study draws strength from a large patient sample and its nationwide multicenter recruitment. It

Conclusions

In conclusion, our work suggests that IVIG is safe therapeutic option that may be effective in improving musculoskeletal involvement, systemic inflammation, digestive tract symptoms and corticosteroid tapering in SSc. Whether or not the stabilization of skin and lung involvement can be considered as a therapeutic success of IVIG remains to be established. Randomized control trials are warranted to confirm these results.

The following are the supplementary data related to this article.

Competing interests

SS received travel fees from LFB. DL received grants from OctaPharma and CSL Behring.

Funding

This work was supported by a grant from OctaPharma.

Acknowledgments

The authors wish to thank the Groupe Francophone de Recherche sur la Sclérodermie (GFRS), the Société Nationale Française de Médecine Interne (SNFMI), the Amicale des Jeunes Internistes (AJI) and the Club Rhumatismes et Inflammations (CRI) for their valuable assistance in this work.

References (49)

  • V. Sobanski et al.

    Current approaches to the treatment of systemic-sclerosis-associated pulmonary arterial hypertension (SSc-PAH)

    Curr Rheumatol Rep

    (2016)
  • E. Hachulla et al.

    Home sequential high dose intravenous immunoglobulins in systemic autoimmune disease

    Ann Rheum Dis

    (2002)
  • S. Kivity et al.

    Evidence for the use of intravenous immunoglobulins—a review of the literature

    Clin Rev Allergy Immunol

    (2010)
  • I. Schwab et al.

    Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

    Nat Rev Immunol

    (2013)
  • V. Molina et al.

    Intravenous immunoglobulin and fibrosis

    Clin Rev Allergy Immunol

    (2005)
  • L. Cantarini et al.

    Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future

    Immunol Res

    (2015)
  • C. Bodemer et al.

    Efficacy of intravenous immunoglobulins in sclerodermatomyositis

    Br J Dermatol

    (1990)
  • Y. Levy et al.

    Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin—a preliminary report

    Clin Rheumatol

    (2000)
  • H. Amital et al.

    Fibrosis regression induced by intravenous gammaglobulin treatment

    Ann Rheum Dis

    (2003)
  • Y. Levy et al.

    Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study

    Arthritis Rheum

    (2004)
  • Y. Asano et al.

    A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion

    Rheumatology

    (2005)
  • Y. Levy et al.

    Response of vasculitic peripheral neuropathy to intravenous immunoglobulin

    Ann N Y Acad Sci

    (2005)
  • H. Ihn et al.

    High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma

    Br J Dermatol

    (2007)
  • F. Nacci et al.

    Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study

    Ann Rheum Dis

    (2007)
  • Cited by (0)

    1

    EH and DL contributed equally to this work.

    View full text